Drug intelligence / Profile preview

Morphomer Tau

Development stage: Unknown
Lead developer: AC Immune
Modality: Small Molecules
Administration: Oral

Overview

Morphomer Tau refers to a program of small molecule Tau aggregation inhibitors developed by AC Immune for the treatment of Alzheimer's disease and other tauopathies. Utilizing the proprietary Morphomer™ platform, these orally bioavailable compounds are designed to cross the blood-brain barrier and selectively bind to misfolded Tau proteins. The mechanism involves preventing the transition of Tau monomers into toxic oligomers and insoluble aggregates (neurofibrillary tangles), thereby potentially halting the progression of neurodegeneration. Lead candidates within this program have included ACI-3024, which was previously partnered with Eli Lilly, and the next-generation compound ACI-12586.

Other names: Tau Morphomer

Targets

Tau aggregates (Microtubule-associated protein tau (pathological form))

Beyond the preview

Go deeper on Morphomer Tau.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Morphomer Tau.

Explore the full profile